Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 24;15(1):330.
doi: 10.1186/s13023-020-01562-x.

Data from the European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC)

Renata S Scalco  1 , Alejandro Lucia  2   3 , Alfredo Santalla  3   4 , Andrea Martinuzzi  5 , Marinela Vavla  5 , Gianluigi Reni  5 , Antonio Toscano  6 , Olimpia Musumeci  6 , Nicol C Voermans  7 , Carlyn V Kouwenberg  7 , Pascal Laforêt  8 , Beatriz San-Millán  9   10 , Irene Vieitez  10 , Gabriele Siciliano  11 , Enrico Kühnle  12 , Rebeca Trost  12 , Sabrina Sacconi  13 , Mads G Stemmerik  14 , Hacer Durmus  15 , Biruta Kierdaszuk  16 , Andrew Wakelin  17 , Antoni L Andreu  18 , Tomàs Pinós  18 , Ramon Marti  18 , Ros Quinlivan  1 , John Vissing  19 ; EUROMAC Consortium
Collaborators, Affiliations

Data from the European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC)

Renata S Scalco et al. Orphanet J Rare Dis. .

Abstract

Background: The European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC) was launched to register rare muscle glycogenoses in Europe, to facilitate recruitment for research trials and to learn about the phenotypes and disseminate knowledge about the diseases through workshops and websites. A network of twenty full and collaborating partners from eight European countries and the US contributed data on rare muscle glycogenosis in the EUROMAC registry. After approximately 3 years of data collection, the data in the registry was analysed.

Results: Of 282 patients with confirmed diagnoses of muscle glycogenosis, 269 had McArdle disease. New phenotypic features of McArdle disease were suggested, including a higher frequency (51.4%) of fixed weakness than reported before, normal CK values in a minority of patients (6.8%), ptosis in 8 patients, body mass index above background population and number of comorbidities with a higher frequency than in the background population (hypothyroidism, coronary heart disease).

Conclusions: The EUROMAC project and registry have provided insight into new phenotypic features of McArdle disease and the variety of co-comorbidities affecting people with McArdle disease. This should lead to better management of these disorders in the future, including controlling weight, and preventive screening for thyroid and coronary artery diseases, as well as physical examination with attention on occurrence of ptosis and fixed muscle weakness. Normal serum creatine kinase in a minority of patients stresses the need to not discard a diagnosis of McArdle disease even though creatine kinase is normal and episodes of myoglobinuria are absent.

Keywords: Glycogen storage disease; International registry; McArdle disease; Metabolic diseases; Myopathy; Rare diseases.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Registered patients by country. UK: United Kingdom; SP: Spain; IT: Italy; NL: Netherlands; FR: France; DE: Germany; DK: Denmark; TR: Turkey; PL: Poland
Fig. 2
Fig. 2
Body mass index (BMI) in 203 adult patients with McArdle disease (GSDV). Underweight: < 18.5; Normal weight: 18.5–24.9; Overweight: 25.0–29.9; Obese I: 30.0–34.9; Obese II: 35.0–39.9; Obese III: ≥ 40 kg/m2
See this image and copyright information in PMC

References

    1. Augustine EF, Adams HR, Mink JW. Clinical trials in rare disease: challenges and opportunities. J Child Neurol. 2013;28:1142–1150. doi: 10.1177/0883073813495959. - DOI - PMC - PubMed
    1. Conwit RA, Bhanushali MJ, Porter JD, et al. Adding more muscle and nerve to clinical trials. Muscle Nerve. 2011;44:695–702. doi: 10.1002/mus.22130. - DOI - PubMed
    1. Stoller JK. The challenge of rare diseases. Chest. 2018;153:1309–1314. doi: 10.1016/j.chest.2017.12.018. - DOI - PubMed
    1. Orphanet_Report_Series. Rare Diseases Registries in Europe2018 May 2018.
    1. EUROMAC registry of patients with McArdle disease and other rare glycogenolytic disorders with exercise intolerance. www.euromacregistry.eu. Accessed 06/05/2018.

Publication types